Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 26;19(10):637–655. doi: 10.1038/s41571-022-00671-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Springer Nature Limited 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

PMC Copyright notice

Fig. 3 — Activating KRAS mutations have numerous implications for the tumour immune microenvironment^87,156, including activation and recruitment of macrophages, polarization of M1 to M2 macrophages, and suppression of CD8⁺ T cells via effects on MHC–T cell receptor (TCR) and PD-L1–PD-1 signalling as well as via activation of myeloid-derived suppressor cells (MDSCs) and regulatory T (T_reg) cells. Together, these alterations in the tumour microenvironment present opportunities for intervention in the treatment of KRAS-mutated malignancies, and pertinent examples are provided. DC, dendritic cell; ICAM1, intercellular adhesion molecule 1.